RZLT
Rezolute, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.96
−1.25%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$4.19
From 52W high−63.80%
Volume1.07M
Market cap$383.05M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$4.19
From 52W high
−63.80%
Volume
1.07M
Market cap
$383.05M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.5x
P/E (TTM)
—
RSI (14)
48.5
MomentumView details →
1D Return
−1.25%
YTD Return
+70.55%
SummaryUpdated Jun 1, 2026
Rezolute, Inc. (NASDAQ:RZLT) is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in Redwood City, California. Originally incorporated as AntriaBio, Inc., the company rebranded to Rezolute in December 2017 to better reflect its focus on developing transformative therapies for metabolic diseases. The company went public in January 2013 and has since dedicated its efforts to addressing rare and complex conditions associated with chronic glucose imbalance, particularly targeting ultra-rare pediatric genetic disorders and diabetic complications.
Similar companies
Latest newsMore news →
Rezolute announced that enrollment is complete in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism, with topline results expected in mid-December 2026.21d agoThe FDA recommended holding a pre-BLA meeting with Rezolute as a precursor to submitting a Biologics License Application for congenital hyperinsulinism.31d ago